Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as emodepside (BAY 44-4400)
emodepside · 1 trial · 3 indications
Determined by negative Kato-Katz thick smears in two stool samples taken at the Test of Cure Visit
| Arm | Type | Description |
|---|---|---|
| Emodepside | EXPERIMENTAL | - |
| Mebendazole | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| emodepside (BAY 44-4400) | DRUG | Treatment with single dose of oral 15 mg emodepside |
| Mebendazole 100 MG | DRUG | Treatment with 100 mg mebendazole orally administered b.i.d. for 3 days |
| similar placebo to mebendazole | DRUG | Treatment with mebendazole similar placebo orally administered b.i.d. for 3 days |
| matching placebo of emodepside | DRUG | Treatment with single dose of oral emodepside matching placebo |
Inclusion Criteria: 1. Male or non-pregnant (confirmed by a negative serum pregnancy test) and non-breastfeeding female participants aged 12 years and older. 2. T. trichiura as a single infection or co-infection with hookworm and/or A. lumbricoides, confirmed by presence of T. trichiura eggs assess...
Emodepside is an investigational small molecule being developed for the treatment of Trichuris trichiura infection, also known as whipworm infection. It is currently in Phase 3 clinical development and is being studied in patients with soil-transmitted helminth infections, including hookworm and Ascaris lumbricoides infections.
Emodepside is being developed by Bayer AG, a German pharmaceutical company. The company's stock is traded over-the-counter under the ticker symbol BAYRY.
Emodepside is currently in Phase 3 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The ongoing Phase 3 trial is designed to evaluate its efficacy and safety in participants with soil-transmitted helminth infections.
Emodepside is being studied in a Phase 3 clinical trial with the identifier NCT06800248. This randomized, double-blind, active-controlled trial is expected to enroll 315 participants aged 12 years and older in the Philippines. The study is not yet recruiting and will evaluate the drug's efficacy and safety in treating Trichuris trichiura, hookworm, and Ascaris lumbricoides infections.
Yes, emodepside is also known as BAY 44-4400. Both names refer to the same investigational drug being developed by Bayer AG for the treatment of soil-transmitted helminth infections.